Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • +44 (0)20 7454 5110
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.

News Releases

view all
    • News in Focus
        • Browse News Releases

        • All Public Company News
        • All Multimedia News
        • View All News Releases

        • Regulatory News

        • D/A/CH Regulatory News
        • UK Regulatory News
        • View All Regulatory News

    • Business & Money
        • Auto & Transportation

        • Aerospace & Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads & Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking & Road Transportation
        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers & Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalisation
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls & Research
        • Trade Show News
        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil & Gas Discoveries
        • Utilities
        • Water Utilities
        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defence
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation & Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking & Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers & Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines & Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics & Personal Care
        • Fashion
        • Food & Beverages
        • Furniture & Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewellery
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film & Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • View All Sports

        • Travel

        • Amusement Parks & Tourist Attractions
        • Gambling & Casinos
        • Hotels & Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Animal Welfare
        • Corporate Social Responsibility
        • Economic News, Trends & Analysis
        • Education
        • Environmental
        • European Government
        • Labour & Union
        • Natural Disasters
        • Not For Profit
        • Public Safety
        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Enquiries
    • Media Enquiries
    • Partnerships
    • Hamburger menu
    • Cision PR Newswire UK provides press release distribution, targeting, monitoring, and marketing services
    • Send a Release
      • Phone

      • +44 (0)20 7454 5110 from 8 AM - 5:30 PM GMT

      • ALL CONTACT INFO
      • Contact Us

        +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • 2 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      • General Enquiries
      • Media Enquiries
      • Partnerships
      • Worldwide Offices
      • Client Login
      • Send a Release
      • Resources
      • Journalists
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Regulatory News
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      Asthma Biologics Market Predicted to Reach USD 19.2 billion by 2031, Growing at a 12.5% CAGR | Exclusive Report by Transparency Market Research

      This image opens in the lightbox

      News provided by

      Transparency Market Research

      23 Oct, 2023, 09:18 GMT

      Share this article

      Share this article


      Asthma biologics are revolutionizing the treatment of severe asthma, offering targeted therapies that address underlying inflammation and improve patients' quality of life.

      WILMINGTON, Del., Oct. 23, 2023 /PRNewswire/ -- The asthma biologics market was estimated to have acquired US$ 6.5 billion in 2022.  It is anticipated to register a 12.5% CAGR from 2022 to 2031, and by 2031, the market is likely to gain US$ 19.2 billion.

      Asthma biologics are shifting towards personalized treatment regimens. With advances in biomarker identification, physicians can better match patients with the right biologic therapy. This tailoring of treatment can lead to improved efficacy and reduced side effects, opening doors for further research and development in this area.

      Download PDF Brochure: https://www.transparencymarketresearch.com/sample/sample.php?flag=S&rep_id=85819 

      Asthma Biologics Market Report Scope:

      Report Coverage

      Details 

      Forecast Period 

      2023-2031

      Base Year 

      2017-2020

      Size in 2022

      US$ 6.5 Bn

      Forecast (Value) in 2031

      More than US$ 19.2 Bn

      Growth Rate (CAGR)

      12.5 %

      No. of Pages

      148 Pages

      Segments covered

      Drug Class, Distribution Channel

      While most of the focus has been on adult patients, there is a growing realization that pediatric asthma represents an underserved market. Developing biologics specifically for children and adolescents could address this gap and create new revenue streams for pharmaceutical companies.

      The rise of telemedicine and digital health platforms offers a unique opportunity to monitor asthma patients remotely, gather real time data, and tailor treatment plans accordingly. These technologies can complement biologics and improve patient adherence, creating a niche for innovative solutions in the market.

      Key Findings of the Market Report

      • Interleukin Inhibitors are currently the dominating drug class in the asthma biologics market, revolutionizing treatment for severe asthma.
      • Retail Pharmacies dominate the distribution channel in the asthma biologics market due to accessibility and patient-pharmacist interaction.
      • North America leads the asthma biologics market, driven by advanced healthcare infrastructure, robust research, and high asthma prevalence.

      Market Trends for Asthma Biologics

      • Asthma biologics are increasingly tailored to individual patient profiles, improving effectiveness and minimizing side effects.
      • The market is expanding to address pediatric asthma, recognizing an underserved demographic.
      • Emerging biologics target non allergic asthma, addressing a substantial patient group.
      • Digital health platforms and telemedicine are integrated for remote patient monitoring, data gathering, and personalized treatment planning.
      • Developing regions in Asia Pacific and Middle East & Africa are witnessing market growth, driven by increasing asthma prevalence and healthcare investments.

      Enquiry Before Buying @ https://www.transparencymarketresearch.com/sample/sample.php?flag=EB&rep_id=85819 

      Global Market for Asthma Biologics: Regional Outlook

      • The asthma biologics market in North America is a dynamic landscape. It is dominated by the United States, where high asthma prevalence, advanced healthcare infrastructure, and substantial R&D investments drive market growth.
      • Europe asthma biologics market is thriving, with the United Kingdom, Germany, and France at the forefront. The region benefits from a robust healthcare system and rising asthma incidence. Personalized medicine is a growing trend, with biologics targeting specific patient profiles.
      • Regulatory agencies like the European Medicines Agency (EMA) ensure high quality standards, fostering innovation. The European market also experiences expansion into non-allergic asthma treatments, emphasizing a holistic approach to asthma management.
      • The Asia Pacific asthma biologics market is evolving rapidly fueled by the surging asthma rates and increased healthcare spending. Countries like Japan, China, and India are key players. The region is focused on pediatric asthma treatments and telemedicine integration, harnessing digital health for better patient care.
      • The market has vast potential, which is attractive to both established pharmaceutical companies and emerging startups. As biologics gain traction, they address the unique healthcare challenges of diverse Asian populations.

      Global Asthma Biologics Market: Key Players

      The competitive landscape of the asthma biologics market is dynamic and marked by both established pharmaceutical giants and innovative biotech companies. Key players like AstraZeneca, GlaxoSmithKline, and Novartis dominate with well established biologics.

      Newer entrants such as Regeneron and Teva Pharmaceuticals challenge the status quo with innovative therapies. Collaboration between companies and academic institutions for research and development is common, fostering innovation.

      The market is intensively regulated, ensuring the highest standards for product quality and safety. As personalized medicine gains prominence, competition centers on developing biologics that target specific patient profiles and offer enhanced efficacy and fewer side effects.The following companies are well-known participants in the global Asthma Biologics market:

      • Amgen, Inc.
      • AstraZeneca
      • F. Hoffmann-La Roche Ltd.
      • GSK plc
      • Novartis AG
      • Regeneron Pharmaceuticals, Inc.
      • Sanofi
      • Teva Pharmaceutical Industries Ltd.
      • Other Prominent Players

      Product Portfolio

      • Amgen, Inc. is renowned for its innovative biopharmaceutical products, focusing on breakthroughs in areas such as oncology, bone health, and cardiovascular disease.
      • AstraZeneca is a global leader in pharmaceuticals, specializing in respiratory, cardiovascular, and oncology medications. They are at the forefront of advanced science and technology.

      Global Asthma Biologics Market Segmentation 

      Drug Class

      • Selective Immuno-suppressants
      • Interleukin Inhibitors
      • Others

      Distribution Channel

      • Retail Pharmacies
      • E-commerce
      • Others

      Region

      • North America
      • Latin America
      • Europe
      • Asia Pacific
      • Middle East & Africa

      Place an Order Copy of Asthma Biologics Market Report at:  https://www.transparencymarketresearch.com/checkout.php?rep_id=85819&ltype=S 

      About Transparency Market Research

      Transparency Market Research, a global market research company registered at Wilmington, Delaware, United States, provides custom research and consulting services. Our exclusive blend of quantitative forecasting and trends analysis provides forward-looking insights for thousands of decision makers. Our experienced team of Analysts, Researchers, and Consultants use proprietary data sources and various tools & techniques to gather and analyses information.

      Our data repository is continuously updated and revised by a team of research experts, so that it always reflects the latest trends and information. With a broad research and analysis capability, Transparency Market Research employs rigorous primary and secondary research techniques in developing distinctive data sets and research material for business reports.

      Contact:

      Nikhil Sawlani
      Transparency Market Research Inc.
      CORPORATE HEADQUARTER DOWNTOWN,
      1000 N. West Street,
      Suite 1200, Wilmington, Delaware 19801 USA
      Tel: +1-518-618-1030
      USA – Canada Toll Free: 866-552-3453
      Website: https://www.transparencymarketresearch.com    
      Blog: https://tmrblog.com    
      Email: sales@transparencymarketresearch.com 

      Logo: https://mma.prnewswire.com/media/1682871/TMR_Logo_Logo.jpg

      Modal title

      Contact PR Newswire

      • +44 (0)20 7454 5110
        from 8 AM - 5:30 PM GMT
      • General Enquiries
      • Media Enquiries
      • Partnerships

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United States
      • Vietnam

      My Services

      • All News Releases
      • PR Newswire Amplify™
      • Resources
      • Journalists
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via Privacy@cision.com 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Customer Portal
      • Resources
      • Journalists
      +44 (0)20 7454 5110
      from 8 AM - 5:30 PM GMT
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookie Settings
      Copyright © 2026 PR Newswire Europe Limited. All Rights Reserved. A Cision company.